Is it possible to avoid weight regain after getting thinner?

Simone Peccin


Obesity is a chronic disorder with a progressive and relapsing profile, and it has reached epidemic
global proportions. It is a preventable and treatable cause of increased early mortality, however, in
most of cases, it reaches only transitory success. When obese people lose weight, orexigen hormones
increase and sacietogen ones decrease, causing a persistent increase in hunger and a decrease in
body energy expenditure. In a obesogenic environment, this metabolic imbalance causes obesity
relapse. The obesity treatment must focus in hyperproteic diets, intensive and frequent exercise and a
combination of drugs that counteract the compensatory mechanisms present in who have lost weight.


Obesity; Treatment; Weight regain.

Full Text:



World Health Organization. Obesity and Overwheight.

Fact Sheet 311, 2015.

Ministério da Saúde. Vigilância de fatores de risco e proteção

para doenças crônicas por inquérito telefônico. Vigitel

Brasil 2014.

Ministério da Saúde. Estratégias para o cuidado da pessoa

com doença crônica. Obesidade. Cadernos de atenção

básica, 38. Ministério da saúde, Brasil, 2014.

Kraschnewski JL, Boan J, Esposito J, Sherwood NE, Lehman

EB, Kephart DK, Sciamanna CN. Long term weight

loss maintenance in the United States. Int J Obes (Lond)

; 34: 1644–1654.

Weiss EC, Galuska DA, Kettel Khan L, Gillespie C, Serdula

MK. Weight regain in U.S. adults who experienced

substantial weight loss, 1999–2002. Am J Prev Med

; 33: 34–40.

Guyenet SJ, Schwartz MW. Clinical review: Regulation of

food intake, energy balance, and body fat mass: implications

for the pathogenesis and treatment of obesity. J.

Clin. Endocrinol. Metab. 2012; 97: 745–755.

Begg DP, Woods SC. The endocrinology of food intake.

Nat. Rev. Endocrinol. 2013; 9: 584–597.

Thaler JP, Guyenet SJ, Dorfman MD, Wisse BE, Schwartz

MW. Hypothalamic Inflammation: Marker or Mechanism

of Obesity Pathogenesis? Diabetes 2013; 62: 2629-2634.

Velloso LA, Schwartz LW. Altered hypothalamic function

in diet-induced obesity J Obes (Lond). 2011 35(12):


Thaler JP, Yi CX, Schur EA ,Guyenet SJ, Hwang BH,

Dietrich MO, Zhao T et al. Obesity is associated with hypothalamic

injury in rodents and humans. J Clin Invest.

; 122(1): 153–162.

MacLean PS, Bergouignan A, Cornier MA, Jackman MR.

Biology’s response to dieting: the impetus for weight

regain Am J Physiol Regul Integr Comp Physiol. 2011;

(3): R581–R600.

Sumithran P, Prendergast LA, Delbridge E, Purcell K,

Shulkes A, Kriketos A, Proietto J. Long-Term Persistence

of Hormonal Adaptations to Weight Loss. N Engl J Med


Rosenbaum M, Hirsch J, Gallagher, Leibel RL. Long-term

persistence of adaptive thermogenesis in subjects who

have maintained a reduced body weight. Am J Clin Nutr

;88:906 –12.

Ochner CN, Tsai AG, Kushner RF, Wadden TA. Treating

obesity seriously: when recommendations for lifestyle

change confront biological adaptations. Lancet Diabetes

Endocrinol 2015; 3(4): 227-304.

MacLean OS, Wing RR, Davidson T, Epstein L, Goodpaster

B, Hall KD, Levin BE, et AL. NIH Working Group

Report: Innovative Research to Improve Maintenance of

Weight Loss. Obesity 2015;23(1): 7-15.

McGuire MT, Wing RR, Klem ML, Hillf JO. Behavioral

Strategies of Individuals Who Have Maintained Long-

-Term Weight Losses. Obesity Research 1999; 7 (4):


Butryn ML, Clark VL, Coletta MC. Behavioral approaches

to the treatment of obesity. In: Akabas SR, Lederman

SA, Moore BJ, editors. Textbook of Obesity: Biological,

Psychological and Cultural Influences. John Wiley &

Sons, 2011: 253-272.

Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth

GD. Effects of energy-restricted high-protein, low-fat

compared with standard-protein, low-fat diets: a meta-

-analysis of randomized controlled trials Am J Clin Nutr


Johansson K, Neovius M, Hemmingsson E. Effects of anti-

obesity drugs, diet, and exercise on weight-loss maintenance

after a very-low-calorie diet or low-calorie diet:a

systematic review and meta-analysis of randomized controlled

trials. Am J Clin Nutr 2014;99:14–23.

Krause WA. Long-term weight loss with sibutramine: a

randomized controlled trial. JAMA. 2001;286(11):1331-

James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner

S, Saris WH, Van Gaal LF. Effect of sibutramine on

weight maintenance after weight loss: a randomised trial.

STORM Study Group. Sibutramine Trial of Obesity Reduction

and Maintenance. Lancet. 2000;356(9248):2119-25.

Astrup A Caterson I, Zelissen P, Guy-Grand B, Carruba

M, Levy B, Sun X, Fitchet M. Topiramate: long-term maintenance

of weight loss induced by a low-calorie diet in

obese subjects. Obes Res. 2004; 12(10):1658-69.

Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP,

Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins

DC, Chung J, Heymsfield SB. Weight control and

risk factor reduction in obese subjects treated for 2 years

with orlistat: a randomized controlled trial. JAMA. 1999

Jan 20;281(3):235-42.

Wadden TA,Hollander P, Klein S, Niswender K, Woo

V,Hale PM, Aronne L. Weight maintenance and additional

weight loss with liraglutide after low-calorie-diet-induced

weight loss: The SCALE Maintenance randomized study.

Int J Obes. 2013; 37(11): 1443-51.

Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB,

Peterson CA, Schwiers M, Day WW, Bowden CH. Two-

-year sustained weight loss and metabolic benefits with

controlled-release phentermine/topiramate in obese and

overweight adults (SEQUEL): a randomized, placebo-

-controlled, phase 3 extension study. Am J Clin Nutr.

; 95(2):297-308.

Yanovski SZ, Yanovski JA. Long-term Drug Treatment for

Obesity: A Systematic and Clinical Review. JAMA. 2014;

(1): 74–86.

Hendricks EJ, Rothman RB, Greenway FL. How physician

obesity specialists use drugs to treat obesity. Obesity

(Silver Spring). 2009;17(9):1730-5.

Hussain HT, Parker JL, Sharma AM. Clinical trial success

rates of anti-obesity agents: the importance of combination

therapies. Obesity reviews (2015) 16: 707–714.



  • There are currently no refbacks.